Supplemental Digital Content 4. Tables - Safety data for participants in groups receiving MenABCWY in the primary or extension study

Table S4_1. Number and percentage of participants with reported solicited local and systemic adverse events during the 7-day post-booster dose period (solicited safety set)

	ABCWY/ ABCWY	ABCWY/ placebo	4CMenB/ ABCWY	ACWY/ ABCWY	ACWY/ placebo
Local adverse events, n (%)					
N	26	24	11	21	19
Any	21 (81)	6 (25)	11 (100)	19 (90)	4 (21)
Pain	20 (77)	6 (25)	11 (100)	19 (90)	17 (89)
Severe	3 (12)	0 (0)	1 (9)	6 (29)	3 (16)
Induration	1 (4)	0 (0)	4 (36)	4 (19)	5 (26)
Severe	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Erythema	4 (15)	0 (0)	3 (27)	3 (14)	5 (26)
Severe	0 (0)	0 (0)	1 (9)	1 (5)	0 (0)
Systemic adverse events, n (%)					
N	26	24	11	21	19
Any	12 (46)	9 (38)	6 (55)	15 (71)	5 (26)
Chills	3 (12)	1 (4)	1 (9)	5 (24)	1 (5)
Severe	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Nausea	0 (0)	2 (9)	3 (27)	4 (19)	1 (5)
Severe	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Fatigue	9 (35)	6 (26)	5 (45)	11 (52)	5 (26)
Severe	1 (4)	0 (0)	0 (0)	1 (5)	0 (0)
Myalgia	6 (23)	2 (9)	1 (10)	8 (38)	1 (5)
Severe	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)
Arthralgia	3 (12)	2 (9)	0 (0)	4 (19)	3 (16)
Severe	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Loss of appetite	2 (8)	1 (4)	1 (9)	8 (38)	2 (11)
Severe	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Headache	7 (27)	6 (26)	5 (45)	12 (57)	2 (11)
Severe	2 (8)	0 (0)	0 (0)	1 (5)	0 (0)
Rash	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)
Severe	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Fever ≥38 °C	2 (8)	0 (0)	0 (0)	0 (0)	0 (0)
Severe	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

N, number of participants with safety results available in each group; n (%), number (percentage) of participants reporting the solicited local/systemic adverse event.

Note: For erythema, “any” was defined from 25mm of diameter. Severe events were defined as “diameter >100 mm” for induration and erythema, “temperature ≥40°C” for fever, and “preventing normal daily activity” for all other adverse events.

Table S4_2. Number and percentage of participants with reported unsolicited adverse events during the 31-day post-booster dose period, by system organ class (unsolicited safety set)

	ABCWY/ ABCWY	ABCWY/ placebo	4MenCB/ ABCWY	ACWY/ ABCWY	ACWY/ placebo
	N=27	N=24	N=11	N=21	N=19
			n (%)		
Any adverse event	6 (22)	4 (17)	3 (27)	6 (29)	4 (21)
At least possibly related	3 (11)	1 (4)	2 (18)	2 (10)	0 (0)
Congenital, familial and genetic disorders	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Eye	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Gastrointestinal	0 (0)	1 (4)	0 (0)	0 (0)	0 (0)
General and administration site conditions	3 (11)	2 (8)	2 (18)	2 (10)	0 (0)
Immune system	0 (0)	0 (0)	0 (0)	0 (0)	1 (5)
Infections and infestations	1 (4)	1 (4)	0 (0)	3 (14)	3 (16)
Injury, poisoning and procedural	0 (0)	0 (0)	0 (0)	1 (5)	0 (0)
Investigations	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Musculoskeletal and connective tissue	1 (4)	0 (0)	0 (0)	0 (0)	0 (0)
Nervous system	1 (4)	0 (0)	1 (9)	1 (5)	0 (0)
Reproductive system and breast	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Respiratory, thoracic and mediastinal	1 (4)	0 (0)	0 (0)	1 (5)	0 (0)
Skin and subcutaneous tissue	0 (0)	0 (0)	1 (9)	0 (0)	0 (0)

N, number of participants with safety results available in each group; n (%), number (percentage) of participants reporting the unsolicited adverse event